Inactivated vaccines. 2. Laboratory indices of protection
Identifieur interne : 000207 ( 1968/Analysis ); précédent : 000206; suivant : 000208Inactivated vaccines. 2. Laboratory indices of protection
Auteurs : W. R. Dowdle ; M. T. Coleman ; S. R. Mostow ; H. S. Kaye ; S. C. SchoenbaumSource :
- Postgraduate Medical Journal [ 0032-5473 ] ; 1973-03.
English descriptors
- Teeft :
- Aichi, Aichi vaccine, Aichi vaccine recipients, Aichi vaccinees, American journal, Attack rate, Attack rates, Control group, Epidemic strain, General virology, Hong kong, Hong kong epidemic, Illness categories, Influenza, Influenza vaccine, Influenza vaccine field trials, Influenza vaccines, Nasal secretions, Neuraminidase, Neuraminidase antigens, Neuraminidase inhibition, Neuraminidase serum antibodies, Percent reduction, Postvaccine, Postvaccine aichi, Present address, Protective effect, Serodiagnosis, Serologic evidence, Serum antibodies, Serum haemagglutination inhibition, Serum neuraminidase inhibition, Titre, Vaccine, Vaccine efficacy, Vaccine groups, Vaccine recipients, Vaccinee, World health organization, Zonal centrifugation.
Abstract
The data from our 1968-69 influenza vaccine field trials are anlaysed and pre-challenge haemagglutinin and neuraminidase serum antibodies are evaluated as indices of protection. Prevention of flu-like disease, fever, confinement to bed, and/or seroconversion to Hong Kong was significantly related to post-vaccine A/Hong Kong/68(H3N2) haemagglutination-inhibition (HI) titres. Prevention of disease was also related, although not significantly statistically in every category, to pre-challenge A/Hong Kong/68 neuraminidase inhibition (NI) titres. The trend was the same regardless of whether the origin of the NI antibody was through A/Aichi/68 or A/Japan/62 vaccines or through pre-Hong Kong influenza infections. In summarizing the data using fever as an index of disease, the attack rate (AR) among volunteers without Hong Kong NI or HI antibody was 45%. Presence of NI antibody, in the absence of HI antibody, significantly reduced the AR to 24%. Those with both NI and HI titres experienced a still lower AR of 14%. Those with HI and NI titres both > 1: 160 ran little risk of disease, with an AR of 7%.
Url:
DOI: 10.1136/pgmj.49.569.159
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000702
- to stream Istex, to step Curation: 000702
- to stream Istex, to step Checkpoint: 001799
- to stream Main, to step Merge: 002E29
- to stream Main, to step Curation: 002C54
- to stream Main, to step Exploration: 002C54
- to stream 1968, to step Extraction: 000207
Links to Exploration step
ISTEX:16109575E23BBBFD5D20686D1CB3B1B3BCCFDFB9Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Inactivated vaccines. 2. Laboratory indices of protection</title><author><name sortKey="Dowdle, W R" sort="Dowdle, W R" uniqKey="Dowdle W" first="W. R." last="Dowdle">W. R. Dowdle</name></author><author><name sortKey="Coleman, M T" sort="Coleman, M T" uniqKey="Coleman M" first="M. T." last="Coleman">M. T. Coleman</name></author><author><name sortKey="Mostow, S R" sort="Mostow, S R" uniqKey="Mostow S" first="S. R." last="Mostow">S. R. Mostow</name></author><author><name sortKey="Kaye, H S" sort="Kaye, H S" uniqKey="Kaye H" first="H. S." last="Kaye">H. S. Kaye</name></author><author><name sortKey="Schoenbaum, S C" sort="Schoenbaum, S C" uniqKey="Schoenbaum S" first="S. C." last="Schoenbaum">S. C. Schoenbaum</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:16109575E23BBBFD5D20686D1CB3B1B3BCCFDFB9</idno><date when="1973" year="1973">1973</date><idno type="doi">10.1136/pgmj.49.569.159</idno><idno type="url">https://api.istex.fr/ark:/67375/NVC-73VZGDX5-9/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000702</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000702</idno><idno type="wicri:Area/Istex/Curation">000702</idno><idno type="wicri:Area/Istex/Checkpoint">001799</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001799</idno><idno type="wicri:doubleKey">0032-5473:1973:Dowdle W:inactivated:vaccines:laboratory</idno><idno type="wicri:Area/Main/Merge">002E29</idno><idno type="wicri:Area/Main/Curation">002C54</idno><idno type="wicri:Area/Main/Exploration">002C54</idno><idno type="wicri:Area/1968/Extraction">000207</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Inactivated vaccines. 2. Laboratory indices of protection</title><author><name sortKey="Dowdle, W R" sort="Dowdle, W R" uniqKey="Dowdle W" first="W. R." last="Dowdle">W. R. Dowdle</name></author><author><name sortKey="Coleman, M T" sort="Coleman, M T" uniqKey="Coleman M" first="M. T." last="Coleman">M. T. Coleman</name></author><author><name sortKey="Mostow, S R" sort="Mostow, S R" uniqKey="Mostow S" first="S. R." last="Mostow">S. R. Mostow</name></author><author><name sortKey="Kaye, H S" sort="Kaye, H S" uniqKey="Kaye H" first="H. S." last="Kaye">H. S. Kaye</name></author><author><name sortKey="Schoenbaum, S C" sort="Schoenbaum, S C" uniqKey="Schoenbaum S" first="S. C." last="Schoenbaum">S. C. Schoenbaum</name></author></analytic><monogr></monogr><series><title level="j">Postgraduate Medical Journal</title><title level="j" type="abbrev">Postgrad Med J</title><idno type="ISSN">0032-5473</idno><idno type="eISSN">1469-0756</idno><imprint><publisher>The Fellowship of Postgraduate Medicine</publisher><date type="published" when="1973-03">1973-03</date><biblScope unit="volume">49</biblScope><biblScope unit="issue">569</biblScope><biblScope unit="page" from="159">159</biblScope></imprint><idno type="ISSN">0032-5473</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0032-5473</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Aichi</term><term>Aichi vaccine</term><term>Aichi vaccine recipients</term><term>Aichi vaccinees</term><term>American journal</term><term>Attack rate</term><term>Attack rates</term><term>Control group</term><term>Epidemic strain</term><term>General virology</term><term>Hong kong</term><term>Hong kong epidemic</term><term>Illness categories</term><term>Influenza</term><term>Influenza vaccine</term><term>Influenza vaccine field trials</term><term>Influenza vaccines</term><term>Nasal secretions</term><term>Neuraminidase</term><term>Neuraminidase antigens</term><term>Neuraminidase inhibition</term><term>Neuraminidase serum antibodies</term><term>Percent reduction</term><term>Postvaccine</term><term>Postvaccine aichi</term><term>Present address</term><term>Protective effect</term><term>Serodiagnosis</term><term>Serologic evidence</term><term>Serum antibodies</term><term>Serum haemagglutination inhibition</term><term>Serum neuraminidase inhibition</term><term>Titre</term><term>Vaccine</term><term>Vaccine efficacy</term><term>Vaccine groups</term><term>Vaccine recipients</term><term>Vaccinee</term><term>World health organization</term><term>Zonal centrifugation</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The data from our 1968-69 influenza vaccine field trials are anlaysed and pre-challenge haemagglutinin and neuraminidase serum antibodies are evaluated as indices of protection. Prevention of flu-like disease, fever, confinement to bed, and/or seroconversion to Hong Kong was significantly related to post-vaccine A/Hong Kong/68(H3N2) haemagglutination-inhibition (HI) titres. Prevention of disease was also related, although not significantly statistically in every category, to pre-challenge A/Hong Kong/68 neuraminidase inhibition (NI) titres. The trend was the same regardless of whether the origin of the NI antibody was through A/Aichi/68 or A/Japan/62 vaccines or through pre-Hong Kong influenza infections. In summarizing the data using fever as an index of disease, the attack rate (AR) among volunteers without Hong Kong NI or HI antibody was 45%. Presence of NI antibody, in the absence of HI antibody, significantly reduced the AR to 24%. Those with both NI and HI titres experienced a still lower AR of 14%. Those with HI and NI titres both > 1: 160 ran little risk of disease, with an AR of 7%.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Coleman, M T" sort="Coleman, M T" uniqKey="Coleman M" first="M. T." last="Coleman">M. T. Coleman</name><name sortKey="Dowdle, W R" sort="Dowdle, W R" uniqKey="Dowdle W" first="W. R." last="Dowdle">W. R. Dowdle</name><name sortKey="Kaye, H S" sort="Kaye, H S" uniqKey="Kaye H" first="H. S." last="Kaye">H. S. Kaye</name><name sortKey="Mostow, S R" sort="Mostow, S R" uniqKey="Mostow S" first="S. R." last="Mostow">S. R. Mostow</name><name sortKey="Schoenbaum, S C" sort="Schoenbaum, S C" uniqKey="Schoenbaum S" first="S. C." last="Schoenbaum">S. C. Schoenbaum</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/1968/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000207 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/1968/Analysis/biblio.hfd -nk 000207 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= 1968
|étape= Analysis
|type= RBID
|clé= ISTEX:16109575E23BBBFD5D20686D1CB3B1B3BCCFDFB9
|texte= Inactivated vaccines. 2. Laboratory indices of protection
}}
| This area was generated with Dilib version V0.6.33. |  |